In-kind nutritional supplementation for household contacts of persons with tuberculosis would be cost-effective for reducing tuberculosis incidence and mortality in India: a modeling study
Pranay Sinha ^{1,2} , Madolyn Dauphinais ² , Madeline E. Carwile ² , C. Robert Horsburgh, Jr. ^{1,2,3} Nicolas A. Menzies ^{4,5}
1. Section of Infectious Diseases, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, MA, USA
2. Boston Medical Center, Boston, MA, USA
3. Department of Epidemiology, Boston University School of Public Health, MA, USA
4. Center for Health Decision Sciences, Harvard TH Chan School of Public Health, Boston, MS USA
5. Department of Global Health and Population, Harvard TH Chan School of Public Health, Boston, MA, USA
* Corresponding author
Abstract word count:249/250 word Body word count: 3369/3500 words References: 30/30
Keywords: Nutritional supplementation, tuberculosis, undernutrition, India, Health Economics
Running title: Nutritional supplementation for TB prevention
Corresponding author: Pranay Sinha, 801 Massachusetts Ave, Crosstown Building, Suite 2021A, Boston, MA, USA 02119; email: psinha@bu.edu; phone: 516-633-9920
Summary : Undernutrition is the leading cause of tuberculosis in India. Using a Markov state-transition model, we found that food baskets for household contacts of persons with tuberculosis would be cost-effective in reducing tuberculosis incidence and mortality in India.
Research in context
<i>Evidence before this study:</i> Undernutrition is the leading risk factor for TB worldwide. Recently, the
RATIONS study demonstrated a roughly 40% reduction in incident TB among household contacts who received in-kind macronutrient and micronutrient supplementation.
Added value of this study: Although the RATIONS study demonstrated a dramatic reduction in incident
TB, it is unclear if nutritional interventions to prevent TB are cost-effective. Previously, only one cost-
effectiveness analysis of nutritional interventions for household contacts has been published. Due to lack
of published data, that study had to make assumptions regarding the impact of nutritional interventions of
TB incidence and mortality. In this study, we conducted an economic evaluation of a RATIONS-style intervention to reduce incident TB and mortality in India using observed data.
Implications of all the available evidence: In-kind nutritional supplementation for household contacts of
individuals with TB disease would be cost-effective in reducing incident TB and TB mortality,
particularly if TB programs leverage economies of scale to bring down the cost of the nutritional intervention.

47 ABSTRACT

- 48 **Background:** Undernutrition is the leading cause of tuberculosis (TB) globally, but nutritional
- 49 interventions are often considered cost prohibitive. The RATIONS study demonstrated that nutritional
- 50 support provided to household contacts of persons with TB can reduce TB incidence. However, the long-
- 51 term cost-effectiveness of this intervention is unclear.
- 52 **Methods:** We assessed the cost-effectiveness of a RATIONS-style intervention (daily 750 kcal dietary
- 53 supplementation and multi-micronutrient tablet). Using a Markov state transition model we simulated
- 54 TB incidence, treatment, and TB-attributable mortality among household contacts receiving the
- 55 RATIONS intervention, as compared to no nutritional support. We calculated health outcomes (TB cases,
- 56 TB deaths, and disability-adjusted life years [DALYs]) over the lifetime of intervention recipients and
- 57 assessed costs from government and societal perspectives. We tested the robustness of results to
- 58 parameter changes via deterministic and probabilistic sensitivity analysis.
- 59 Findings: Over two years, household contacts receiving the RATIONS intervention would experience 39%
- 60 (95% uncertainty interval (UI): 23–52) fewer TB cases and 59% (95% UI: 44–69) fewer TB deaths. The
- 61 intervention was estimated to avert 13,775 (95% UI: 9036–20,199) TB DALYs over the lifetime of the
- 62 study cohort comprising 100,000 household contacts and was cost-effective from both government
- 63 (incremental cost-effectiveness ratio: \$229 per DALY averted [95% UI: 133–387]) and societal
- 64 perspectives (\$184 per DALY averted [95% UI: 83–344]). The results were most sensitive to the cost of
- 65 the nutritional supplement.
- 66 Interpretation

Prompt nutritional support for household contacts of persons with TB disease would be cost-effective in
 reducing TB incidence and mortality in India.

- 69
- 70
- 71
- 72

73 INTRODUCTION

74	Tuberculosis (TB) has regained its position as the leading infectious cause of death worldwide, with 10.6		
75	million cases and 1.3 million deaths in 2022.(1) Undernutrition blunts the innate and adaptive immune		
76	response to Mycobacterium tuberculosis, the pathogen that causes TB.(2) At least 2.2 million of 10.6		
77	million TB cases are attributable to undernutrition, making it the leading risk factor for TB.(1) There is		
78	also evidence that, among individuals diagnosed with TB disease, undernourished individuals face higher		
79	risks of death, treatment failure, and relapse despite undergoing antimycobacterial therapy.(2, 3)		
80	Historical data suggest that nutritional supplementation could have a beneficial role by reducing the		
81	incidence of TB disease and reducing case fatality among those with TB disease.(2) However, in the		
82	absence of contemporary empirical data, nutritional supplementation for persons with TB (PWTB) and		
83	their household contacts (HHCs) has not been widely adopted.		
84			
85	The recently published RATIONS study randomized more than 10,000 household contacts of persons		
86	with TB in eastern India between a control arm that received routine TB care with no additional in-kind		
87	nutritional supplementation and an intervention arm that received macronutrient and micronutrient		
88	support with a food basket that cost \$13 per month for 6 months.(4) Compared to the control group,		
89	the intervention group experienced a 40% reduction in TB incidence over the following two years. PWTB		
90	in the RATIONS study, who also received nutritional support regardless of whether their household		
91	contacts were in the control or intervention groups, experienced an approximately 35% reduction in		
92	mortality compared to a previous National TB Elimination Program cohort. The RATIONS study shows		
93	the potential nutritional supplementation to prevent TB incidence and mortality among household		
94	contacts of PWTB.		

95

- 96 In this study, we developed a Markov state transition model to explore if a RATIONS-style nutritional
- 97 intervention would be cost-effective for reducing TB incidence and mortality in India.
- 98 METHODS
- 99
- 100 Study Design
- 101 We used a Markov cohort model to estimate the long-term costs and health outcomes of providing a
- 102 food basket to HIV-negative household contacts of PWTB in India. We parameterized intervention costs
- 103 and effect sizes from the results of the RATIONS study, which was conducted among household contacts
- 104 of PWTB in Jharkhand, India, in a largely rural population with a high degree of multidimensional
- 105 poverty.(4) We conducted the study from the perspective of India's central government, which funds
- 106 the National TB Elimination Program (NTEP). Recognizing that patient costs can often be substantially
- 107 larger than provider costs, we also conducted a secondary analysis to estimate results from a societal
- 108 perspective, considering costs borne by both patients and the Indian government. We programmed the
- 109 model using TreeAge Pro v.22.2.0 (Tree Age, Williamstown, MA).
- 110

111 Intervention strategies

- 112 We modeled two strategies. The "usual intervention" strategy reflects the status quo wherein
- 113 household contacts and PWTB do not receive any in-kind nutritional support. In the RATIONS
- 114 intervention, HHCs of PWTB receive a food basket that contains a daily multi-micronutrient tablet, rice,
- and lentils for 6 months.(4) The food basket provides 23g of protein and a total of 750 Kcal calories daily.
- 116 In addition, under the RATIONS intervention we assumed that individuals progressing to TB disease
- 117 would receive a nutritional supplement that provided 1200 Kcal with 52g of protein for all six months of
- 118 TB treatment.
- 119

120 Study Model

121	The Markov model simulates the natural course of TB incidence, cure, and sequelae for a starting cohort			
122	without TB disease. The model was constructed as a set of mutually exclusive health states, with natural			
123	history transitions represented by movements between these health states: development of TB disease,			
124	TB cure, death from TB, and death from other causes (Figure 1). Parameters defining TB incidence rates			
125	were specified to represent differences in the rates of progression to TB disease based on individual			
126	nutritional status. Individuals developing TB disease could die, self-cure, or be cured via treatment.			
127	Individuals who survive TB transition to an early post-treatment state, where they have an elevated risk			
128	of recurrent disease for 12 months as well as increased all-cause mortality. Following 12 months in the			
129	early-post treatment phase, individuals transition to the late post-treatment phase, where they continu			
130	to have increased all-cause mortality, but where their risk of TB disease falls to baseline. We assumed			
131	that after surviving TB, individuals would have a lower average quality of life due to chronic post-TB lun			
132	disease. We used the model to simulate progression of a cohort of 100,000 household contacts of PWT			
133	through these health states over their lifetime, with a 6-month time step.			
134				
135	Parameter inputs			
136				
137	Health Outcomes			
138	Outcomes from the simulation included TB disease incidence, TB deaths, disability-adjusted life years			
139	(DALYs), and costs from the government perspective. In a secondary analysis, we also considered costs			
140	from a societal perspective. All outcomes were assessed over the lifetime of the modelled cohort.			
141				
142	We sourced TB incidence rates for HHCs after exposure from a previous meta-analysis.(5) Table 1			

143 presents incidence estimates adopted for the analysis for the first five years. After five years of elevated

144	risk of TB disease, we assumed the incidence would drop to prevailing rates in the general Indian		
145	population based on WHO estimates. (3) To account for the long-term secular declines in population TB		
146	incidence rates, we assumed a 3% annual decline based on incidence trends estimated for India over the		
147	past five years (Supplementary Figure 1). In the early post-treatment phase, we assumed that TB		
148	survivors had an increased risk of recurrent TB based on observed data from India.(6) In the late post-		
149	treatment phase, the risk dropped to baseline.		
150			
151	We obtained TB case fatality rates from the WHO Global TB Report 2022.(3) For background mortality		
152	rates, we constructed TB-deleted life tables using WHO life tables.(7) For individuals surviving TB, we		
153	estimated a lifetime increase in TB-attributable mortality using previous conservative estimates.(8)		
154			
155	To calculate DALYs, we obtained disability weights for TB disease from the Global Burden of Disease		
156	Study 2019.(9) We estimated the disability weight for TB survivors (due to persistent sequelae) to be		
157	0.053 based on a published study of the global burden of post-TB lung disease.(10)		
158			
159	Intervention impact		
160	We assumed that prompt nutritional supplementation would reduce the risk of incident TB disease		
161	among HHCs. Based on the results of the RATIONS study, we assumed an incidence rate ratio of 0.61		
162	(95% CI 0·43, 0·85) for HHCs receiving supplementation compared to no supplementation for two years		
163	from the beginning of the intervention. After two years, we assumed that those receiving the		
164	intervention and those receiving usual care had a similar risk of incident TB disease. We assumed that		
165	PWTB who receive nutritional support have reduced TB-related mortality based on a comparison of		
166	outcomes of PWTB in the RATIONS study to an NTEP cohort, operationalized as a risk ratio of 0.65 (95%		
167	CI: 0·49, 0·85) applied between TB incidence and cure.(6, 11)		

168

169	We used cost data from the RATIONS study, which reported supplementation costs of \$13 per month		
170	inclusive of delivery costs. In sensitivity analyses, we examined a wide range of values for the cost of the		
171	nutritional supplementation, to account for regional variation, diversion of food grains, and wastage. We		
172	obtained TB treatment costs from a recent published study.(12) For costs borne by TB patients and		
173	affected households, we assumed that the direct medical costs, direct non-medical costs, and		
174	productivity losses borne by TB-affected household would be \$700 (SD: 140) per TB episode.(13, 14) We		
175	rounded all costs to the nearest dollar. All costs are reported in 2022 US dollars.		
176			
177	Cost-effectiveness analysis		
178	We employed the model to compare the RATIONS nutritional supplementation intervention to the		
179	status quo. We projected TB cases, TB deaths, disability-adjusted life-years (DALYs) attributable to TB,		
180	and costs for each strategy over the lifetime of the study cohort. We calculated incremental cost-		
181	effectiveness ratios (ICERs) as the ratio of mean incremental costs to mean incremental health benefits,		
182	for the intervention compared to the usual care strategy. Costs and DALYs were discounted at 3% per		
183	annum.(15)		
184			
185	Willingness-to-pay		
186	We derived our willingness-to-pay (WTP) threshold from Ochalek et al., who estimated country-specific		
187	willingness-to-pay thresholds based on the opportunity cost of healthcare spending.(16) For India, this		
188	study estimated a WTP threshold equivalent to 23% of per-capita GDP (US\$550 in 2022). We considered		
189	ICERs below this threshold to be clearly cost-effective.		
190			

191 Sensitivity analysis

192	To assess the robustness of our results, we conducted both deterministic and probabilistic sensitivity			
193	analyses.(17) For the deterministic sensitivity analysis, we defined <i>a priori</i> feasible ranges around core			
194	parameter values (Table 1) and then repeated the analysis multiple times, each time varying one			
195	parameter between the maximum and minimum of the feasible range, with other parameters held at			
196	their point estimate. Next, we conducted two-way sensitivity analyses, in which we simultaneously			
197	varied the parameters that emerged as the most important from one-way sensitivity analyses.			
198				
199	Lastly, we performed probabilistic sensitivity analysis (PSA). We defined uncertainty in parameter values			
200	as probability density functions (PDFs) for each model parameter. We then employed 2 nd -order Monte			
201	Carlo simulation to repeat the analysis 10,000 times, each time drawing a random value for each model			
202	parameter from its PDF. This produced 10,000 estimates for each model outcomes, with the distribution			
203	of these estimates quantifying the uncertainty in model outcomes due to the combined uncertainty			
204	from all model parameters. We report the PSA results using cost-effectiveness acceptability curves.(18)			
205	In addition, we report uncertainty around main analysis results using 95% uncertainty intervals			
206	calculated from the PSA results.			
207				
208	RESULTS			
209	Base Case Results			
210	Base case results are presented in Table 2. Per 100,000 household contacts, those receiving the			
211	RATIONS intervention had lower cumulative TB incidence over their lifetime compared to those			
212	receiving usual care (6749 cases [95% uncertainty interval (UI): 5524–8520] vs. 7718 [95% UI: 6261–			
213	9734]), risk ratio (RR) 0.87 [95% UI: 0.83–0.93]). In the first two years of this model, there were 1580 TB			
214	cases (95% UI: 1074–2461) in the RATIONS intervention as opposed to 2577 TB cases (95% UI: 1898–			

3634) with usual care, RR 0.61 (0.48–0.77). These results are consistent with the empirical findings of
the RATIONS trial.

217

218	The cohort receiving the RATIONS intervention was also estimated to have lower lifetime TB mortality		
219	(906 [95% UI: 667–1288] vs. 1529 [95% UI: 1196–2044] TB deaths, RR 0.59 [95% UI: 0.49–0.72]). In the		
220	first two years, there were 198 TB deaths (95% UI: 127–335) under the RATIONS intervention vs. 479		
221	(95% UI: 343–710) under the usual care strategy (RR 0.41 [95% UI:0.31–0.56]). Per 100,000 individuals,		
222	the RATIONS intervention averted 13,775 DALYs (95% UI: 9036–20,199) compared to usual care. The		
223	majority of DALYs were averted in the RATIONS arm through reductions in TB mortality. Disaggregated		
224	4 DALY estimates for each strategy are reported in Table 3.		
225			
226	Under the governmental perspective total (discounted) costs for the usual care strategy were \$0.76		
227	million (95% UI: 0.52–1.11) per 100,000 individuals, representing the costs of treatment for individuals		
228	developing TB. Total governmental costs under the RATIONS intervention were \$3.93 million (95% UI:		
229	2.89–5.18), with \$0.66 million (95% UI: 0.45–0.96) of this total due to the costs of TB care, and the		
230	remainder due to the costs of the nutritional intervention. Under the societal perspective total cost		
231	were \$5.24 million (95% UI: 2.97–5.68) for the usual care strategy. Total societal costs under the		
232	RATIONS intervention were \$7.76 million (95% UI: 5.71-10.58).		
233			
234	The incremental cost-effectiveness ratio of the RATIONS intervention, as compared to the status quo,		

was \$229 per DALY averted (95% UI: 133–387) under the healthcare perspective and \$184 (95% UI: 83–
344) under the societal perspective. Both these estimates are below the country specific WTP threshold
of \$550 per DALY averted.

238

239 Sensitivity analysis

240	One-way sensitivity analyses for the general population showed that the two parameters with the		
241	greatest impact on the ICER were the pre-recipient cost of the RATIONS supplementation (baseline		
242	assumption: \$28.5, range: \$20-100) and the risk ratio of TB incidence for those receiving the nutritional		
243	supplementation (baseline assumption: 0.61, range: 0.43 to 0.85) (Table 4). In threshold analyses, the		
244	cost-effectiveness ratio for the RATIONS intervention was below to the WTP threshold (\$550 per DALY		
245	averted) when the cost of supplementation was less than \$75, indicating that the intervention would be		
246	cost-effective for any supplementation cost below this value. Even when we assumed the risk ratio for		
247	TB incidence was 0.99, the WTP threshold was not exceeded. The model was less sensitive to the risk		
248	reduction in TB mortality, the cost of TB treatment, and the disability weight for post-TB lung disease		
249	(Table 4).		
250			
250	In two-way sensitivity analyses, the RATIONS intervention was cost-effective across a large range of		
251	costs of the supplement and risk ratio of TB incidence (Figure 3). When the cost of the supplement for		
252	HHCs was below \$56, the intervention was always cost-effective from the government perspective.		
253			
	When considering the societal perspective, the intervention remained below the WTP threshold as long		
254	When considering the societal perspective, the intervention remained below the WTP threshold as long as the supplementation cost was below \$59. We also conducted a two-way sensitivity analysis of the risk		
254 255			
	as the supplementation cost was below \$59. We also conducted a two-way sensitivity analysis of the risk		
255	as the supplementation cost was below \$59. We also conducted a two-way sensitivity analysis of the risk ratios for TB incidence and TB mortality. Even at the lowest estimates of the risk ratio for TB incidence		
255 256	as the supplementation cost was below \$59. We also conducted a two-way sensitivity analysis of the risk ratios for TB incidence and TB mortality. Even at the lowest estimates of the risk ratio for TB incidence		
255 256 257	as the supplementation cost was below \$59. We also conducted a two-way sensitivity analysis of the risk ratios for TB incidence and TB mortality. Even at the lowest estimates of the risk ratio for TB incidence (0.85) and TB mortality (0.85), the RATIONS intervention remained cost-effective with an ICER of \$514.		
255 256 257 258	as the supplementation cost was below \$59. We also conducted a two-way sensitivity analysis of the risk ratios for TB incidence and TB mortality. Even at the lowest estimates of the risk ratio for TB incidence (0.85) and TB mortality (0.85), the RATIONS intervention remained cost-effective with an ICER of \$514.		

effectiveness acceptability curves demonstrate the points at which RATIONS becomes consistently cost-effective (Figure 3).

264

265 **DISCUSSION**

266 Nutritional interventions to mitigate risks of TB incidence and mortality are often perceived to be cost 267 prohibitive. However, the RATIONS study has provided empirical evidence that low-cost nutritional 268 support could have a substantial impact on lowering the risk of incident TB in settings with high rates of 269 multidimensional poverty and undernutrition. Our analysis suggests that an in-kind nutritional 270 intervention modelled on the food basket used in the RATIONS study could be cost-effective for 271 reducing TB incidence and mortality in India. We estimated that RATIONS-style nutritional support 272 would have a cost-effectiveness of \$229 per DALY averted from a healthcare perspective and \$184 per 273 DALY averted from a societal perspective. Our findings can help national TB programs as they consider 274 the economics of implementing nutritional support to reduce the incidence of TB among household 275 contacts. 276 277 Balanced nutritional interventions likely reduce incident TB disease by enhancing the humoral and 278 innate responses to *Mycobacterium tuberculosis*; these responses can help infected individuals

eliminate or contain the bacilli.(2) Nutritional support to malnourished individuals may acutely restore

their immune response. Indeed, mouse models suggest that providing a protein-rich diet to protein-

281 deficient mice can restore their anti-tubercular immune response within two weeks.(19) Given that the

282 majority of TB disease in high burden settings arises from infection within the past two years, nutritional

support should be provided to HHCs promptly after the diagnosis of the index case to prevent incident

TB disease.(20)

285

286	In our model, we limited the reduction in TB incidence among HHCs to two years after exposure since		
287	this was the duration of follow-up observed in the RATIONS study. For subsequent years, we assumed		
288	that individuals receiving the RATIONS intervention would have the same incidence rate as the usual		
289	care group, which remained elevated in years 3, 4, and 5 since exposure. Given the impact of nutritiona		
290	support on the immune response to TB, it is possible that individuals receiving improved nutrition are		
291	more resistant to new TB infection. If so, the incidence reductions produced by the RATIONS		
292	intervention could extend beyond the two years assumed in this analysis. As such, our health impact and		
293	cost-effectiveness estimates may be conservative.		
294			
295	It is important to note that that the RATIONS study—on which this cost-effectiveness analysis was		

based—was conducted in a population with high levels of material deprivation and undernutrition, and

297 TB incidence rates higher than those estimated for other parts of India. It is possible that the impact and

298 cost-effectiveness of nutritional support may be lower in settings with a lower prevalence and severity

of undernutrition, or lower TB incidence. Our two-way sensitivity analysis suggests that even at the

300 lowest estimates of risk reduction for TB incidence (15% reduction) and mortality (15% reduction), the

301 intervention would remain below the WTP threshold. These are credible effect sizes in less

302 impoverished populations. A systematic review, which largely drew on data from high income countries,

303 found a log-linear relationship between BMI and TB incidence wherein TB incidence decreases by

304 approximately 14% per 1kg/m² increase in BMI which is entirely achievable in 6 months on the RATIONS

305 intervention. Further, a systematic review of randomized trials of macronutrient supplementation in

306 PWTB, despite being underpowered, estimated that macronutrient supplementation was associated

307 with a RR of 0.34 (95% CI: 0.10–1.20) for TB mortality.(21)

308

309	Public health investments to eliminate TB and undernutrition have historically provided some of the
310	greatest returns on investment. (22, 23) The ICER estimated for nutritional support in our study is
311	considerably below both the country-specific WTP threshold for India and the ICER for well-accepted TB
312	preventive interventions, such as test-driven isoniazid preventive therapy for persons with HIV/AIDS
313	(\$1154 per DALY averted).(24) In our model, the ICER was most sensitive to the cost of nutritional
314	supplementation for HHCs. Even when we assumed the lowest possible effect of nutritional
315	interventions on incident TB disease, nutritional support would be cost-effective at \$56 per recipient
316	over 6 months, which was nearly twice the cost of the intervention. It is possible that state and national
317	governments would enjoy economies of scale, not possible in the context of a clinical trial, that
318	consequently could further lower the cost of the intervention.
319	
320	Our analysis has several limitations. First, we did not model the impact of nutritional interventions on
321	reducing early relapses and disengagement from care, even though these are plausible effects.(2, 25)
322	Second, we did not account for reductions in TB transmission and secondary TB cases that might result
323	from lower TB incidence, and instead focused on the direct health benefits experienced by intervention
324	recipients. Third, our cost assumptions were limited to drug-susceptible TB, which is less costly to treat
325	than drug-resistant TB, (13) and we also did not model the medical and non-medical costs faced by
326	PWTB prior to their diagnosis. Approximately two-thirds of Indian PWTB treated in the public sector first
327	seek care in the private sector and accrue large costs before an accurate TB diagnosis is made.(13) Forth,
328	the model did not capture the positive externalities of nutritional support, including improvements in
329	nutritional status and functional recovery and improved economic productivity among TB survivors,
330	which have been explored in a previous analysis. (26) Taken together, these limitations suggest that our
331	ICER estimates will be conservative, and that nutritional support could be even more cost-effective than
332	we project.

\mathbf{a}	\mathbf{a}	\mathbf{a}
- 1	1	1
\mathcal{I}	$\boldsymbol{\cdot}$	\mathcal{I}

334	Improvements in population-level nutrition and progress on social determinants of health likely
335	contributed to the massive decline in TB incidence and mortality in countries like the United States and
336	the United Kingdom that occurred even prior to the introduction of antimicrobials.(25) The striking
337	findings of the RATIONS study have demonstrated the role nutritional interventions can play in the
338	contemporary era to accelerate TB elimination. India is well positioned to institute a large-scale
339	nutritional support program as it already has well-established infrastructure for delivering in-kind
340	rations, mid-day meals, and nutritional counseling.(27-29) The TB Mitra Program, which crowdsources
341	nutritional support for persons with TB, could also be scaled up.(30)
342	
343	Additional research is necessary to help us understand how to target nutritional interventions equitably
344	and efficiently. Operational studies are needed to design optimal delivery systems. Even as nutritional
345	interventions are operationalized in settings with lower prevalence of undernutrition in India,
346	epidemiological studies can help us understand the effect size of nutritional interventions in diverse
347	populations. We also need clinical and translational studies to better define the nutritional needs of
348	special populations, such as pregnant women and children, to develop the best possible nutritional
349	package. Economic evaluations should be conducted alongside nutritional intervention studies to inform
350	policy.
351	
352	In conclusion, our analysis projected that a RATIONS-style intervention would be cost-effective for
353	populations with a high dual burden of TB and undernutrition in India and drive large reductions in TB
354	incidence and mortality among household contacts of persons with TB.
255	

- 355
- 356

357 FUNDING

- 358 This work was supported by the National Institutes of Health [grant number K01AI167733-01A1 to PS];
- 359 the Burroughs Wellcome/ASTMH Postdoctoral fellowship to PS; US Civilian Research and Development
- 360 Foundation [grant number USB-31150-XX-13 to PS] with federal funds from the Government of India's
- 361 Department of Biotechnology, the Indian Council of Medical Research, the National Institutes of Health,
- 362 the National Institute of Allergy and Infectious Diseases, and the Office of AIDS Research and distributed
- in part by CRDF Global [DAA3-19-65673-1]; grant from the Warren Alpert Foundation to PS); and a
- 364 career investment award by the Department of Medicine at Boston University Chobanian & Avedisian
- 365 School of Medicine. The funders had no role in study design, analysis, or reporting.

366

367 **CONFLICTS OF INTEREST**

368 We do not report any conflicts of interest.

370 TABLES AND FIGURES

Table 1: Model assumptions

Model Parameters	Point estimate (Ranges)	Distribution	Sources
Monthly cost of nutritional support for household contacts	\$4.75 (standard deviation: 0.95)	Gamma	Bhargava et al. (2023)(4)
Monthly cost of nutritional support for persons with TB			
Cost of nutritional support for persons with TB (6 months)	\$14.7 (standard deviation: 2.9)	Gamma	Bhargava et al. (2023)(11)
Cost of TB treatment (healthcare perspective)	\$102.77 (standard deviation: 15)	Gamma	Chatterjee et al. (2021)(12)
Cost of TB treatment (societal perspective)	\$700 (standard deviation: 70)	Gamma	Sinha et al. (2020) (13) Portnoy et al. (2023) (14)
Risk ratio incidence	0.61 (0.43-0.85)	PERT	Bhargava et al. (2023) (4)
Risk ratio mortality	0.65 (0.49-0.85)	PERT	Bhargava et al. (2023)(11) Velayutham et al. (2018)(6)
Start Age	40 years	-	
TB Incidence rate per 100,000	Year 1: 1478 (897-2427) Year 2: 831 (624-1106) Year 3: 1101 (757-1599) Year 4: 492 (344-704) Year 4: 549 (415-726) Beyond year 5: National TB incidence rates declining at 3% annually	-	Fox et al (2013).(5) Global TB report 2022(1)
Case fatality rate	17% (12%-24%)	PERT	WHO global TB report 2022(1)
Annual disability weight of TB disease	0.333 (0.224-0.454)	Beta	Global burden of disease 2019 (9)
Annual disability weight for post- TB disability	0.053 (0.026-0.079)	Beta	Quaife et al. (2020) (10)
Post-TB mortality risk ratio	1.14 (1.02-1.34)	PERT	Menzies et al. (2021) (8)
Risk of recurrent TB after treatment completion	0.13 (0.10-0.16)	Beta	Velayutham et al. (2018)

Table 2: Outcomes per 100,000 individuals

385 (DALYs: disability-adjusted life years; ICER: incremental cost effectiveness ratio [\$/DALYs averted]. Costs
 386 and DALYs discounted)

Strategy	Strategy DALYs (95% CI)		Healthcare ICER (95% CI)	Societal cost (95% CI)	Societal ICER (95% ICER)	
Usual care	41,172 (35,673-49,015)	\$0.76 million (0.52-1.11)	Ref	\$5.24 million (2.97-5.68)	Ref	
RATIONS	27,397 (22,208-35,452)	\$ 3.93 million (2.89-5.18)	\$229 (133-387)	\$7.76 million (5.71-10.58)	\$184 (83-344)	

390 Table 3: Sources of DALYs per 100,000 in the two strategies

Component of Disability-adjusted Life Years	Usual care	RATIONS
	29,705	16,951
Years lost to TB mortality	(22,820-40,615)	(12,298-24,682)
	6,209	5,760
Years lost to incremental post-TB mortality	(2087-13,596	(1958-12,589)
	1,245	1,071
Years lost to disability from TB disease	(877-1784)	(756-1538)
	4,013	3,615
Years lost to disability from post-TB chronic lung disease	(2910-5544)	(2626-5027)
	41,172	27,397
Total	(35,673-49,015)	(22,208-35,452)

413 Table 4: Results of one-way sensitivity analyses from a healthcare perspective

Variable Description	Variable Low	Variable Base	Variable High	Impact on ICER	ICER Low	ICER High
Incremental cost of supplement						
for HHC (\$)	20	28.5	100	Increase	125	675
Risk ratio of TB incidence	0.43	0.61	0.85	Increase	132	288
Risk ratio of TB mortality	0.49	0.65	0.85	Increase	147	262
Case fatality rate in usual group	0.12	0.17	0.24	Decrease	142	237
Incremental cost of supplement						
for PWTB (\$)	40	88.2	200	Increase	161	236
Probability of TB recurrence	0.04	0.06726	0.12	Decrease	171	191
Cost of TB treatment (\$)	100	700	300	Decrease	214	229
Annual disability weight of post-						
TB lung disease	0.0265	0.053	0.0795	Decrease	181	186
Risk ratio of post-TB mortality	1.02	1.14	1.34	Decrease	183	184

442 Figure 1: State transition diagram of model






Figure 3: Two-way sensitivity analysis of the cost of intervention and risk ratio of TB incidence Areas

shaded blue denote that the intervention would be clearly cost-effective and red shaded regions


indicate that the willingness-to-pay threshold of \$550 was exceeded from the government perspective and usual care is preferred.






493 Figure 4: Cost-effectiveness acceptability curves

- 494 Cost-effectiveness acceptability curves for the models with A. government perspective and B. societal
- 495 perspective. The blue line denotes the RATIONS intervention, and the red line indicates usual care. X-
- 496 axis denotes willingness-to-pay and the Y-axis denotes the percentage of iterations (out of 10,000
- 497 iterations) in which a particular strategy was favored for a particular willingness-to-pay threshold. Areas
- 498 shaded blue are below the willingness-to-pay threshold of \$550 and those shaded red are above that
- 499 threshold.
- 500 A.



504

Supplementary Figure 1: TB incidence assumptions for the model. The first five years, the incidence is
 elevated as reported in a previous systematic review.(5) Thereafter, we projected that the incidence
 would drop to the TB incidence rate in India as defined in the WHO Global Tuberculosis Report 2022. We
 assumed an annual 3% decrease in incidence due to secular reasons.



532 References

- 533
- 534 **1.** World Health Oranization. Global tuberculosis report 2022. WHO, Geneva. 2022.
- 535 2. Sinha P, Davis J, Saag L, Wanke C, Salgame P, Mesick J, et al. Undernutrition and tuberculosis:
- 536 public health implications. The Journal of infectious diseases. 2019;219(9):1356-63.
- 537 3. Sinha P, Ponnuraja C, Gupte N, Babu SP, Cox SR, Sarkar S, et al. Impact of Undernutrition on
- 538 Tuberculosis Treatment Outcomes in India: A Multicenter Prospective Cohort Analysis. Clin
- 539 Infect Dis. 2022.
- 540 4. Bhargava A, Bhargava M, Meher A, Benedetti A, Velayutham B, Teja GS, et al. Nutritional
- 541 supplementation to prevent tuberculosis incidence in household contacts of patients with
- 542 pulmonary tuberculosis in India (RATIONS): a field-based, open-label, cluster-randomised,
- 543 controlled trial. The Lancet. 2023.
- 544 5. Fox GJ, Barry SE, Britton WJ, Marks GB. Contact investigation for tuberculosis: a systematic
- review and meta-analysis. European Respiratory Journal. 2013;41(1):140-56.
- 546 6. Velayutham B, Chadha VK, Singla N, Narang P, Gangadhar Rao V, Nair S, et al. Recurrence of
- 547 tuberculosis among newly diagnosed sputum positive pulmonary tuberculosis patients treated
- 548 under the Revised National Tuberculosis Control Programme, India: A multi-centric prospective
- 549 study. PLoS One. 2018;13(7):e0200150.
- 550 7. World Health Organization. Life tables by country: India [Available from:
- 551 <u>https://apps.who.int/gho/data/view.main.60740?lang=en.</u>
- 552 8. Menzies NA, Quaife M, Allwood BW, Byrne AL, Coussens AK, Harries AD, et al. Lifetime
- 553 burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis 554 sequelae. The Lancet Global health. 2021;9(12):e1679-e87.
- 9. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369
- 556 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the
- 557 Global Burden of Disease Study 2019. The Lancet. 2020;396(10258):1204-22.
- 558 10. Quaife M, Houben RM, Allwood B, Cohen T, Coussens AK, Harries AD, et al. Post-
- tuberculosis mortality and morbidity: valuing the hidden epidemic. The Lancet Respiratorymedicine. 2020;8(4):332.
- 561 11. Bhargava A, Bhargava M, Meher A, Teja GS, Velayutham B, Watson B, et al. Nutritional
- 562 support for adult patients with microbiologically confirmed pulmonary tuberculosis: outcomes
- 563 in a programmatic cohort nested within the RATIONS trial in Jharkhand, India. The Lancet
- 564 Global Health. 2023;11(9):e1402-e11.
- 565 12. Chatterjee S, Toshniwal M, Bhide P, Sachdeva K, Rao R, Laurence Y, et al. Costs of TB
- 566 services in India (No 1). The International Journal of Tuberculosis and Lung Disease.
- 567 2021;25(12):1013-8.
- 568 13. Sinha P, Carwile M, Bhargava A, Cintron C, Acuna-Villaorduna C, Lakshminarayan S, et al.
- 569 How much do Indians pay for tuberculosis treatment? A cost analysis. Public Health Action.
- 570 2020;10(3):110-7.
- 571 14. Portnoy A, Yamanaka T, Nguhiu P, Nishikiori N, Baena IG, Floyd K, et al. Costs incurred by
- 572 people receiving tuberculosis treatment in low-income and middle-income countries: a meta-
- 573 regression analysis. The Lancet Global Health. 2023;11(10):e1640-e7.

- 574 15. Wilkinson T, Sculpher MJ, Claxton K, Revill P, Briggs A, Cairns JA, et al. The International
- 575 Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought. Value
- 576 Health. 2016;19(8):921-8.
- 577 16. Ochalek J, Lomas J, Claxton K. Estimating health opportunity costs in low-income and
- 578 middle-income countries: a novel approach and evidence from cross-country data. BMJ global
- 579 health. 2018;3(6):e000964.
- 580 17. Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD. Model parameter
- estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices
 Task Force--6. Value Health. 2012;15(6):835-42.
- 583 18. Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves--facts, fallacies and 584 frequently asked questions. Health Econ. 2004;13(5):405-15.
- 585 19. Chan J, Tian Y, Tanaka KE, Tsang MS, Yu K, Salgame P, et al. Effects of protein calorie
- 586 malnutrition on tuberculosis in mice. Proceedings of the National Academy of Sciences.
- 587 1996;93(25):14857-61.
- 588 20. Dowdy DW, Behr MA. Are we underestimating the annual risk of infection with
- 589 Mycobacterium tuberculosis in high-burden settings? The Lancet Infectious Diseases.
- 590 2022;22(9):e271-e8.
- 591 21. Grobler L, Nagpal S, Sudarsanam TD, Sinclair D. Nutritional supplements for people being
- 592 treated for active tuberculosis. Cochrane Database of Systematic Reviews. 2016;2016(6).
- 593 22. Estill J, Islam T, Houben RM, Rudman J, Ragonnet R, McBryde ES, et al. Tuberculosis in the
- 594 Western Pacific Region: Estimating the burden of disease and return on investment 2020–2030
- in four countries. The Lancet Regional Health–Western Pacific. 2021;11.
- 596 23. Hoddinott J, Rosegrant M, Torero M. Hunger and malnutrition. Copenhagen Consensus;597 2012.
- 598 24. Kapoor S, Gupta A, Shah M. Cost-effectiveness of isoniazid preventive therapy for HIV-
- infected pregnant women in India. The International Journal of Tuberculosis and Lung Disease.2016;20(1):85-92.
- 601 25. Carwile ME, Hochberg NS, Sinha P. Undernutrition is feeding the tuberculosis pandemic: a
- 602 perspective. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. 2022:100311.
- 603 26. Sinha P, Lakshminarayanan SL, Cintron C, Narasimhan PB, Locks LM, Kulatilaka N, et al.
- 604 Nutritional Supplementation Would Be Cost-Effective for Reducing Tuberculosis Incidence and
- 605 Mortality in India: The Ration Optimization to Impede Tuberculosis (ROTI-TB) Model. Clinical
- 606 infectious diseases : an official publication of the Infectious Diseases Society of America.607 2022;75(4):577-85.
- 608 27. Bhattacharya S, Falcao VL, Puri R. The Public Distribution System in India: Policy Evolution
- and Program Delivery Trends. In: Bhattacharya S, Falcao VL, Puri R, editors. The 15 Billion
- 610 People Question: Food, Vouchers, or Cash Transfers?: The World Bank; 2017. p. 43-105.
- 611 28. Navaneethan P, Kalaivani T, Rajasekaran C, Sunil N. Nutritional status of children in rural
- 612 India: a case study from Tamil Nadu, first in the world to initiate the Mid-Day Meal scheme.
- 613 Health. 2011;3(10):647.
- 614 29. Scott K, Glandon D, Adhikari B, Ummer O, Javadi D, Gergen J. India's auxiliary nurse-
- 615 midwife, anganwadi Worker, and accredited social health activist programs. Health for the
- 616 People: National Community Health Programs from Afghanistan to Zimbabwe Edited by Perry H
- 617 Washingon, DC, USA: USAID/Maternal and Child Survival Program. 2020:113-33.

618 30. National Tuberculosis Elimination P. Ni-kshay Mitra. Ministry of Health & Family Welfare.